Sana Biotechnology reported financial results and received FDA feedback on its IND filing.
1 report, 1 independent
Updated Aug 12
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Sana Biotechnology reported financial results and received FDA feedback on its IND filing.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Sana Biotechnology is advancing its IND application with GMP Master Cell Bank development and trials conducted at Uppsala University Hospital.Sub-event
Sana Biotechnology received FDA feedback on its IND filing and presented results at ADA.1 source
Keep exploring
The entities involved
-
Sana Biotechnology
biotechnology company
Nothing else this week.
- FDA
Related events
- A company submitted study data supporting a PMA submission to the FDA.
- FDA provided guidance for HCW Biologics' IND application.
- FDA approval boosts the Korean drug industry, driving market attention for companies like SamChunDang Pharm.
- ACP guidance aligns with FDA label updates, prompting the Senate to hold hearings on the changes.
- FDA is willing to review updated submissions, while biotech hubs leverage AI to ease clinical development bottlenecks.
Coverage
Newest first; wire copies grouped- GlobeNewswireSana Biotechnology Reports Second Quarter 2025 Financial Results and Business Updates Presented positive 6-month clinical results of ongoing type 1 diabetes study showing that hypoimmune-modified pan